FibroScan® and Fatty Liver (MASLD) Screening Programme
Early assessment of liver health enables better and more confident health management
Liver diseases (e.g. fatty liver) often present no obvious symptoms in their early stages. Many patients are only diagnosed when the condition has already progressed to liver fibrosis or cirrhosis. To help individuals gain early insight into their liver health, CUHK Medical Clinic launches the “FibroScan® and Fatty Liver (MASLD) Screening Programme” (Programme) that offers a liver elastography (FibroScan®) and Fatty Liver Assessment. These non-invasive assessments analyse liver stiffness and fat accumulation, support early identification of common liver conditions, and monitor progression of diseases that affect the liver.
What is Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)?
Metabolic Dysfunction-Associated Steatotic Liver Disease (or MASLD)1 is one of the most common chronic liver diseases, with an estimated global prevalence of up to 38% 2.
In Hong Kong, approximately one in four adults is affected by fatty liver 3.
- If left unmanaged, excessive accumulation of fat in the liver may progress to steatohepatitis, and may further develop into liver fibrosis, cirrhosis, and even liver cancer.
- It is important to note that MASLD is not limited to individuals with obesity. It can also be found in individuals who are not overweight or obese.
Refernence
1. According to the European clinical guidelines on liver and metabolic health issued in 2024, the term “Metabolic Dysfunction-Associated Steatotic Liver Disease” (MASLD) has replaced the former term “Non-Alcoholic Fatty Liver Disease” (NAFLD) to better reflect its association with metabolic conditions.“EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).” Journal of Hepatology, 2024; 81, 492-542
2. Wong VW, Ekstedt M, Wong GL, Hagström H. “Changing epidemiology, global trends and implications for outcomes of NAFLD.” Journal of Hepatology, 2023 Sep;79(3):842-852. doi: 10.1016/j.jhep.2023.04.036. Epub 2023 May 9. PMID: 37169151.
3. 中大肝臟護理中心: 脂肪肝會變肝硬化：研究證「兩步驟篩查法」助及早發現 | 香港中文大學-閱肝｜專業健康資訊｜擺脫腸胃肝病 Retrieved 20 April 2026
Programme Features |
|---|
Non-invasive
Assess degree of liver fibrosis
Effective measurement of liver stiffness and fatty liver condition
Assess impact of chronic liver inflammation on liver tissue
Who is Suitable? |
|---|
Recommended for individuals who have the following conditions:
Diabetes
High blood pressure, high blood sugar, and/or high cholesterol ("three highs")
Overweight or obese
Long-term alcohol consumption habits
Diagnosed with Hepatitis B or Hepatitis C
Have a family history of liver disease
Insulin resistance
Known to have fatty liver disease
FibroScan® is NOT suitable for individuals who have the following conditions:
Pregnant
Implanted with cardiac pacemakers / implantable cardioverter-defibrillators
Programme Details |
|---|
FibroScan® and Fatty Liver (MASLD) Screening Programme
_1778559231.jpg)
Doctor's personalised consultation before check-up
Blood Pressure, Height, Weight & Body Mass Index
HbA1c (Glycated Haemoglobin)
Total Cholesterol
Total Cholesterol / HDL ratio
Non-high-density Lipoprotein Cholesterol
Triglycerides
High-density Lipoprotein & Low-density Lipoprotein Cholesterol
Total Protein, Albumin, Globulin
ALT
Gamma GT
Alkaline Phosphatase
AST
Total Bilirubin
FibroScan® (Liver Fibrosis Scan)*
Medical report with doctor's comments and explanation
HK$2,150
*Fibroscan will be conducted at third-party service location. Please contact us for further details.
Important Notes
- Doctor’s consultation under this Programme will be provided by designated doctor(s).
- This Programme requires advance appointment.
- Fibroscan® is only applicable to individuals of 18 years old or above.
- Please avoid staying up late, consuming alcohol, or engaging in strenuous exercise the day before the examination.
- Fasting for 4 hours is required before Fibroscan®.
- Before performing any test, please notify the doctor of any medication that you are currently using, especially medication used on long-term basis for diseases such as hypertension, diabetes, and/or cardiovascular diseases.
- During the examination, please follow the instructions of the medical team. If you experience any discomfort, please inform the team immediately.
- If the doctor determines that you are not suitable to receive the services under this Programme, or this Programme is not applicable to you, CUHK Medical Clinic will only charge doctor consultation fee and (if applicable) any related diagnostic and/or medication fees/charges according to its/their prevailing prices.
- Fibroscan® will be conducted at third-party service location. Please contact us for further details.
- All items included in this Programme are fixed. No refund or item substitution will be arranged if you are unable to complete any part of this Programme for any reason.
- No promotional offer or discount is applicable to this Programme.
- In case of any dispute, the decision of CUHK Medical Clinic Limited shall be final and conclusive.
CUHK Medical Clinic
(Tsim Sha Tsui)
3468 7141
5/F, Podium Plaza, 5 Hanoi Road, Tsim Sha Tsui, KLNSat 9:30AM – 1:30PM
